Employees with ADHD Aren’t Reaching Their Full Potential at Work, Akili Study Finds
12 Outubro 2023 - 9:00AM
Business Wire
Respondents struggle with routine tasks, career
setbacks, and limited treatment options; meanwhile, managers feel
unprepared to provide support
Akili, Inc. (Nasdaq: AKLI), the leading digital medicine company
behind EndeavorOTC™, today released results from a new study
examining the ways in which ADHD impacts the U.S. workforce. Akili
engaged Wakefield Research to survey 500 employees with ADHD to
better understand the experience of working with ADHD, as well as
500 managers to explore how prepared workplaces are to support
employees with ADHD.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20231012838446/en/
An image showing two people collaborating
in an open-space office accompanied by the title "Build a Better
Workplace for Those with ADHD." (Photo: Business Wire)
The study found that nearly all employees with ADHD (97%) think
they would be capable of accomplishing more if they could better
manage their symptoms. Employees pointed to several ways their ADHD
poses challenges, including:
- Struggling with routine tasks: 2 in 3 employees (65%)
agreed that accomplishing day-to-day work tasks while managing
their symptoms poses a moderate to significant challenge.
Respondents cited several struggles they commonly face, including
being easily distracted (59%) and lack of focus and engagement
(56%).
- Facing emotional and social impacts: Challenges with
ADHD at work aren’t just related to attention. Social and emotional
issues also come into play, with respondents reporting heightened
emotions or sensitivity to rejection or criticism (37%), impulsive
decision-making (35%), and difficulty building relationships with
colleagues (32%).
- Dealing with career setbacks: Most employees (87%)
believe ADHD has contributed to negative career events, including
receiving a negative performance evaluation (39%), being passed
over for a promotion (37%), or having core responsibilities taken
away (27%), all of which can slow down career trajectory.
- Coping with resulting mental health issues: Difficulty
managing ADHD symptoms at work caused a majority of respondents
(71%) to feel anxious. Employees also reported feeling unmotivated
(44%), depressed (40%), defeated (35%), and hopeless (31%).
- Worrying about stigma amongst their colleagues: Almost
all (92%) are concerned about what would happen if their co-workers
learned about their condition, indicating fears about having their
ADHD dismissed or minimized (45%), receiving unsolicited advice
(43%), having co-workers act awkward around them (41%), or being
ridiculed (27%).
Despite the many ways that ADHD can affect an employee’s success
and well-being at work, care options are drastically limited.
- Most employees are trying to manage their symptoms, but
aren’t seeing results: 94% of respondents confirmed that they
use treatments or methods to address their ADHD. However, of the
94% of respondents who confirmed that they use treatments or
methods to address their ADHD, most (78%) would still need more
support to reach their full potential at work.
- There simply aren’t enough treatment options for ADHD:
95% of employees feel limited by the number of treatment options
available to them, and 88% confirmed that they’ve been directly
impacted by the ongoing stimulant medication shortage.
With so many employees with ADHD expressing how difficult it can
be to manage their symptoms at work, it’s vital that employers
provide appropriate accommodations and support systems. However,
Akili’s study found that there is a significant gap between
managers’ level of familiarity with ADHD and their ability to
adequately support an employee who discloses their diagnosis.
- Managers understand that ADHD can significantly impact
someone’s work life: Most managers (83%) are very or extremely
familiar with ADHD, and more than half (54%) recognize that it
would present a moderate to significant challenge for their
employees in executing day-to-day work tasks.
- However, managers aren’t sure what to do if an employee
tells them they have ADHD: More than half (59%) expressed that
they wouldn’t feel completely prepared to appropriately respond if
one of their employees disclosed their diagnosis to them.
- Managers hold on to biases about ADHD: Nearly all (92%)
employees believe that misconceptions about ADHD exist at their
workplace, and that fear is not irrational. More than 9 in 10
managers (93%) would have concerns about an employee who disclosed
their ADHD diagnosis, including their ability to handle complex
assignments (56%) or do the job at all (45%).
The study found that employees are willing and eager to work
with their leaders on how best to manage symptoms in order to feel
more successful. When managers and employees are on the same page,
it helps folks with ADHD receive the support and understanding they
need.
- Employees want their managers to know they have ADHD:
Most employees (85%) have disclosed their ADHD diagnosis to a
supervisor, and the majority of them (79%) are happy with their
choice.
- Employees are looking for support and resources from their
managers: In sharing their diagnosis, employees are looking for
acceptance of how their work style may be different from that of
their colleagues (55%); better awareness of how their supervisor
can support them (54%); and discussions about where and why they
struggle with some tasks (44%). They also want to better understand
the medical benefits specific to their condition (30%) and the
workplace resources (24%) that are available to them.
- Understanding is the most important benefit: more than 9
out of 10 employees (93%) said that having a supervisor who knows
how to support and work with them is more valuable than any other
office benefit or perk.
“ADHD impacts an estimated 11 million adults in the U.S.,
meaning that it’s inevitably prevalent across the workforce.
However, our study highlights the lack of access to care for this
condition, and it plainly shows that people are struggling at work
because of it,” said Scott Kollins, Chief Medical Officer of Akili.
“97% of the study’s employee respondents felt that they could
accomplish more at work if they could better manage their symptoms.
This overwhelming majority makes it clear that we need to rethink
treatment, resources, and understanding across the board.”
Earlier this year, Akili released EndeavorOTC, a game-based ADHD
treatment for adults, built with technology from the world’s first
FDA-authorized video game treatment for pediatric patients with
ADHD, EndeavorRx. EndeavorOTC has been clinically proven to improve
attention and focus in adults with ADHD. The treatment is available
on Android’s Google Play™ and Apple’s iOS App Store®, providing an
accessible treatment option for American adults living with ADHD. A
more comprehensive look at the data can be found at
https://www.akiliinteractive.com/workplacesurvey.
Methodology
The Akili Employee Survey was conducted by Wakefield Research
(www.wakefieldresearch.com) among 500 currently employed U.S.
adults (49% female; 50% male; 1% non-binary) who have been
diagnosed with ADHD, across a range of employers, between August
28th and September 6th, 2023, using an email invitation and an
online survey. Participants were required to attest to having been
diagnosed with ADHD by a professional and were recruited from
across the U.S.
The Akili Managers Survey was conducted by Wakefield Research
(www.wakefieldresearch.com) among 500 U.S. managers (40% female;
60% male), across a range of employers, between August 28th and
September 6th, 2023, using an email invitation and an online
survey. Participants were recruited from across the U.S.
All participants provided written informed consent. Participants
were compensated at fair market value. All data collected were
de-identified, and only aggregate data were analyzed and
presented.
About EndeavorOTC and EndeavorRx
Akili’s suite of cognitive treatment products for ADHD includes
EndeavorOTC and EndeavorRx.
EndeavorOTC is a digital therapeutic indicated to improve
attention function, ADHD symptoms and quality of life in adults 18
years of age and older with primarily inattentive or combined-type
ADHD. EndeavorOTC utilizes the same proprietary technology
underlying EndeavorRx, a prescription digital therapeutic indicated
to improve attention function in children ages 8-12. EndeavorOTC is
available under the U.S. Food and Drug Administration’s current
Enforcement Policy for Digital Health Devices for Treating
Psychiatric Disorders During the Coronavirus Disease 2019
(COVID-19) Public Health Emergency. EndeavorOTC has not been
cleared or authorized by the U.S. Food and Drug Administration for
any indications. It is recommended that patients speak to their
health care provider before starting EndeavorOTC treatment. No
serious adverse events have been reported in any of our clinical
studies. To learn more, visit EndeavorOTC.com.
EndeavorRx is indicated to improve attention function as
measured by computer-based testing in children ages 8 to 12 years
old with primarily inattentive or combined-type ADHD, who have a
demonstrated attention issue. Patients who engage with EndeavorRx
demonstrate improvements in a digitally assessed measure Test of
Variables of Attention (TOVA®) of sustained and selective attention
and may not display benefits in typical behavioral symptoms, such
as hyperactivity. EndeavorRx should be considered for use as part
of a therapeutic program that may include clinician-directed
therapy, medication and/or educational programs, which further
address symptoms of the disorder. EndeavorRx is available by
prescription only. It is not intended to be used as a stand-alone
therapeutic and is not a substitution for a child’s medication. The
most common side effect observed in children in EndeavorRx’s
clinical trials was a feeling of frustration, as the game can be
quite challenging at times. No serious adverse events were
associated with its use. EndeavorRx is recommended to be used for
approximately 25 minutes a day, 5 days a week, over initially at
least 4 consecutive weeks, or as recommended by your child’s health
care provider. To learn more about EndeavorRx, please visit
EndeavorRx.com.
About Akili
Akili is pioneering the development of cognitive treatments
through game-changing technologies. Akili’s approach of leveraging
technologies designed to directly target the brain establishes a
new category of medicine – medicine that is validated through
clinical trials like a drug or medical device, but experienced like
entertainment. Akili’s platform is powered by proprietary
therapeutic engines designed to target cognitive impairment at its
source in the brain, informed by decades of research and validated
through rigorous clinical programs. Driven by Akili’s belief that
effective medicine can also be fun and engaging, Akili’s products
are delivered through captivating action video game experiences.
For more information, please visit www.akiliinteractive.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231012838446/en/
Caty Reid VP, Marketing & Communications
PR@akiliinteractive.com
Akili (NASDAQ:AKLI)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Akili (NASDAQ:AKLI)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024